|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
1,250,000,000 |
Market
Cap: |
79.81(B) |
Last
Volume: |
6,087,366 |
Avg
Vol: |
8,704,124 |
52
Week Range: |
$63.43 - $87.29 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 259 |
Guru Rank Value : 4.6 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
2,000 |
25,472 |
38,458 |
80,792 |
Total Sell Value |
$145,920 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
Total People Sold |
1 |
3 |
3 |
4 |
Total Sell Transactions |
1 |
5 |
9 |
14 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Telman Deborah H |
EVP, Corporate Affairs & GC |
|
2024-01-25 |
4 |
D |
$80.23 |
$15,565 |
D/D |
(194) |
7,082 |
|
- |
|
Telman Deborah H |
EVP, Corporate Affairs & GC |
|
2024-01-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
514 |
7,276 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2024-01-16 |
4 |
AS |
$85.78 |
$428,900 |
D/D |
(5,000) |
101,534 |
|
-24% |
|
Mercier Johanna |
Chief Commercial Officer |
|
2024-01-09 |
4 |
AS |
$85.23 |
$702,466 |
D/D |
(8,242) |
82,729 |
|
-21% |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2023-12-10 |
4 |
D |
$79.02 |
$94,350 |
D/D |
(1,194) |
106,534 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2023-12-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,617 |
107,728 |
|
- |
|
Parsey Merdad |
Chief Medical Officer |
|
2023-12-10 |
4 |
D |
$79.02 |
$100,276 |
D/D |
(1,269) |
71,640 |
|
- |
|
Parsey Merdad |
Chief Medical Officer |
|
2023-12-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,779 |
72,909 |
|
- |
|
Patterson Sandra |
SVP, Controllership |
|
2023-12-10 |
4 |
D |
$79.02 |
$17,542 |
D/D |
(222) |
30,420 |
|
- |
|
Patterson Sandra |
SVP, Controllership |
|
2023-12-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
518 |
30,642 |
|
- |
|
Mercier Johanna |
Chief Commercial Officer |
|
2023-12-10 |
4 |
D |
$79.02 |
$98,538 |
D/D |
(1,247) |
90,971 |
|
- |
|
Mercier Johanna |
Chief Commercial Officer |
|
2023-12-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,730 |
92,218 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2023-12-10 |
4 |
D |
$79.02 |
$264,006 |
D/D |
(3,341) |
387,691 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2023-12-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,347 |
391,032 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2023-11-10 |
4 |
D |
$75.92 |
$61,040 |
D/D |
(804) |
105,111 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2023-11-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,912 |
105,915 |
|
- |
|
Telman Deborah H |
EVP, Corporate Affairs & GC |
|
2023-10-25 |
4 |
D |
$78.39 |
$19,049 |
D/D |
(243) |
6,762 |
|
- |
|
Telman Deborah H |
EVP, Corporate Affairs & GC |
|
2023-10-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
514 |
7,005 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2023-10-17 |
4 |
AS |
$80.00 |
$400,017 |
D/D |
(5,000) |
104,003 |
|
-9% |
|
Parsey Merdad |
Chief Medical Officer |
|
2023-09-12 |
4 |
AS |
$76.99 |
$115,562 |
D/D |
(1,501) |
70,130 |
|
2% |
|
Mercier Johanna |
Chief Commercial Officer |
|
2023-09-10 |
4 |
D |
$76.00 |
$95,456 |
D/D |
(1,256) |
89,488 |
|
- |
|
Mercier Johanna |
Chief Commercial Officer |
|
2023-09-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,730 |
90,744 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2023-09-10 |
4 |
D |
$76.00 |
$255,816 |
D/D |
(3,366) |
383,685 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2023-09-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,348 |
387,051 |
|
- |
|
Patterson Sandra |
SVP, Controllership |
|
2023-09-10 |
4 |
D |
$76.00 |
$11,324 |
D/D |
(149) |
30,124 |
|
- |
|
1105 Records found
|
|
Page 2 of 45 |
|
|